MRVI in the 13F filings
Maravai Lifesciences HLDGS I · CUSIP 56600D107
- Quarter end
- 31 Dec 2023
- the date the book describes
- Filed
- 14 Feb 2024
- latest of these filings; the earliest 8 Feb 2024
- Managers listing it
- 3
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q3 2023 and Q4 2023; 2 listed it in both
- Shares listed
- 11,188,627
- combined, among listed positions
- Reported value
- $73m
- combined, at the quarter end
Among the 93 comparable managers: 2 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing MRVI in Q4 2023
3 of 3 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| MFS Investment Management | 6,014,575 | $39m | under 0.1% | Trimmed | -2,138,905 | 8 Feb 2024 (the filing on sec.gov) |
| AQR Capital Management LLC | 3,504,111 | $23m | under 0.1% | Added | n.a. | 14 Feb 2024 (the filing on sec.gov) |
| Hudson Bay Capital Management LP | 1,669,941 | $11m | 0.07% | Added | +1,010,544 | 14 Feb 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Hudson Bay Capital Management LPexisting position · 1,669,941 shares now+1,010,544
Reductions
- MFS Investment Managementexisting position · 6,014,575 shares now-2,138,905
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 11 | $410m | n.a. | n.a. |
| Q1 2021 | 4 | $230m | n.a. | n.a. |
| Q2 2021 | 8 | $819m | n.a. | n.a. |
| Q3 2021 | 10 | $1.4bn | n.a. | n.a. |
| Q4 2021 | 6 | $900m | n.a. | n.a. |
| Q1 2022 | 4 | $342m | n.a. | n.a. |
| Q2 2022 | 4 | $447m | n.a. | n.a. |
| Q3 2022 | 7 | $527m | n.a. | n.a. |
| Q4 2022 | 8 | $360m | n.a. | n.a. |
| Q1 2023 | 8 | $291m | n.a. | n.a. |
| Q2 2023 | 7 | $234m | n.a. | n.a. |
| Q3 2023 | 6 | $155m | n.a. | n.a. |
| Q4 2023 | 3 | $73m | 2 | 1 |
| Q1 2024 | 5 | $110m | 2 | 3 |
| Q2 2024 | 6 | $91m | 4 | 2 |
| Q3 2024 | 1 | $34m | 1 | 1 |
| Q4 2024 | 1 | $251k | n.a. | n.a. |
| Q3 2025 | 1 | $1.3m | 1 | 0 |
| Q4 2025 | 1 | $5.8m | 13 | 9 |
| Q1 2026 | 1 | $7.1m | 13 | 7 |
| Q2 2026 | 2 | $24m | 19 | 7 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MRVI and LLY →MRVI and JNJ →MRVI and VRTX →Choose a stock to compare with MRVI →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MRVI, latest filings →Back to the 13F Explorer →